A.M. Vitals: A Genetic Test Pegging the Odds of Living Past 100
Also: legal battles over health-care overhaul begin; AstraZeneca gets fined by an E.U. court; excess swine flu vaccine stocks headed for the trash.
CDC Team’s XMRV-Chronic Fatigue Syndrome Paper Is Out
Researchers looking at the blood of 51 people with CFS and 56 healthy people found no association between XMRV and the syndrome.
Swedish Trial Finds Prostate-Cancer Screening Saves Lives
The accompanying editorial says that “current programs that raise awareness and provide balanced information about the pros and cons of screening seem to be the right way forward.”
A Decade Later, Human Genome Project Yields Few New Cures
The primary goal of the $3 billion Human Genome Project — to ferret out the genetic roots of common diseases like cancer and Alzheimer’s and then generate treatments — remains largely elusive.
As ASCO Kicks Off, Amgen Hopes Prolia Will Become Cancer Drug
If Prolia is approved for use in cancer, global sales could hit $3 billion by mid-decade, some analysts say.
Caution: This Blog Post May Be Under Embargo
ASCO embargoes plus company press releases plus prior data release equals confusion.
Consumers Not Too Psyched About ‘Evidence-Based Health Care’
A study published does not bring good news for proponents of “evidence-based health care.”
What Does the Dartmouth Atlas Data Say About U.S. Health Care?
The NYT reports today that extracting savings from the health-care system may not be as simple as bringing high-spending areas into line with lower-spending ones.
A.M. Vitals: Pre-ASCO Studies on Drugs, Ovarian Cancer Screening
Also: the U.K.’s NICE in the crosshairs, NIH unveils conflict-of-interest policy for researchers.
Does Human Growth Hormone Actually Do Anything for Athletes?
Until this month, there wasn’t much solid evidence that HGH improves aspects of athletic performance.
